E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to severe plaque psoriasis |
Psoriasi a placche da moderata a severa |
|
E.1.1.1 | Medical condition in easily understood language |
Psoriasis is a systemic inflammatory disorder that causes red, raised scaly patches on the skin.
|
La psoriasi è un disordine infiammatorio sistemico che causa macchie rosse, squamose sulla pelle. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Skin and Connective Tissue Diseases [C17] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071117 |
E.1.2 | Term | Plaque psoriasis |
E.1.2 | System Organ Class | 100000004858 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Efficacy of mirikizumab induction dosing compared to secukinumab and placebo in subjects based on sPGA (0,1) and PASI 90 at Week 16 |
Efficacia del trattamento di induzione con mirikizumab rispetto a secukinumab e placebo nei pazienti sulla base di sPGA (0,1) e PASI 90 alla settimana 16
|
|
E.2.2 | Secondary objectives of the trial |
Efficacy of mirikizumab induction dosing compared to placebo based on PASI 75 at Week 4; PASI 75, PASI 100, BSA =1% , PSS symptoms score of 0 in those with a PSS symptoms score =1 at baseline and DLQI (0,1) with at least a 5-point improvement (reduction) from baseline with DLQI baseline score =5 at week 16 |
Efficacia del trattamento di induzione con mirikizumab rispetto a placebo sulla base del PASI 75 alla settimana 4; PASI 75, PASI 100, BSA <=1%, punteggio, PSS per la sintomatologia pari a 0 nei soggetti con un punteggio PSS per la sintomatologia >=1 al basale e DLQI (0,1) con un punteggio DLQI (0,1) alla settimana 16 con almeno 5 punti di miglioramento (riduzione) rispetto al basale con DLQI al basale >=5 alla settimana 16. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Present with chronic plaque psoriasis based on an investigator-confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to baseline, and meet the following criteria:: a) involving =10% body surface area (BSA) and absolute PASI score =12 in affected skin at screening (Visit 1) and baseline (Visit 2), and b) sPGA score of =3 at screening (Visit 1) and baseline (Visit 2). - Candidate for systemic therapy and/or phototherapy - Female patients must test negative for pregnancy prior to initiation of treatment and agree to use contraception for the duration of the trial - Are =18 years of age
|
Il paziente presenta psoriasi a placche cronica in base a diagnosi confermata dallo sperimentatore di psoriasis vulgaris cronica da almeno 6 mesi prima del basale e soddisfa i criteri seguenti: a) interessamento di una superficie corporea (BSA) =10% e punteggio PASI assoluto =12 nelle aree cutanee colpite allo screening (visita 1) e al basale (visita 2) e b) punteggio sPGA =3 allo screening (visita 1) e al basale (visita 2). - Candidato alla terapia sistemica e/o alla fototerapia - Le pazienti di sesso femminile devono ottenere un test di gravidanza negativo prima dell’avvio del trattamento e devono impegnarsi a utilizzare un metodo contraccettivo per tutta la durata della sperimentazione - Età =18 anni
|
|
E.4 | Principal exclusion criteria |
- Have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disease or abnormal laboratory values at screening, that in the opinion of the investigator, would potentially affect patient safety within the study or of interfering with the interpretation of data. - Are women who are breastfeeding or plan to breastfeed during study - Have had serious, opportunistic or chronic/recurring infection within 3 months prior to screening - Have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study. - Have any other skin conditions (excluding plaque psoriasis) that would affect interpretation of the results - Have received systemic nonbiologic therapy within 28 days prior to baseline - Have received topical treatment within 14 days prior to baseline - Have prior use of secukinumab - Have received anti-tumor necrosis factor (TNF) targeting biologics within 8 weeks prior to baseline - Have previous exposure to any biologic therapy targeting IL-12/23 (p40 subunit) or IL-23 (p19 subunit) or IL-17, either marketed or investigational. |
Malattia instabile o non controllata, inclusa (a titolo esemplificativo e non esaustivo) malattia cerebrovascolare, respiratoria, epatica, renale, gastrointestinale, endocrina, ematologica o neurologica o anomalie dei valori di laboratorio allo screening che, a giudizio dello sperimentatore, siano suscettibili di compromettere la sicurezza del paziente nel contesto dello studio o di interferire con l’interpretazione dei dati. - Donne in allattamento o che prevedano di allattare nel corso dello studio - Infezione seria, opportunistica o cronica/recidivante nei 3 mesi precedenti lo screening - Vaccinazione con bacillo di Calmette-Guérin (BCG) nei 12 mesi precedenti o somministrazione di vaccini vivi (inclusi vaccini vivi attenuati) nelle 12 settimane precedenti il basale o pazienti che prevedano di assumere uno qualsiasi di tali agenti nel corso dello studio. - Presenza di altre condizioni cutanee (diverse dalla psoriasi a placche) suscettibili di interferire con l’interpretazione dei risultati - Terapia sistemica non biologica nei 28 giorni precedenti il basale - Terapia topica nei 14 giorni precedenti il basale - Uso pregresso di secukinumab - Trattamento con biologici anti-fattore di necrosi tumorale (TNF) nelle 8 settimane precedenti il basale - Esposizione pregressa a qualsiasi terapia biologica diretta contro l’IL-12/23 (subunità p40) o l’IL-23 (subunità p19) o l’IL-17, in commercio o sperimentale.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Static Physician's Global Assessment (sPGA)(0,1) and Psoriasis Area and Severity Index 90 (PASI 90) |
sPGA (static Physician’s Global Assessment) (0,1) e indice PASI 90 (Psoriasis Area and Severity Index 90)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Timepoints to assess whether mirikizumab induction dosing is superior to placebo: Week 16- sPGA (0,1) PASI 90 Timepoints to assess whether mirikizumab induction dosing is noninferior to secukinumab: Week 16- sPGA (0,1) PASI 90 |
Timepoint per la valutazione della superiorità del trattamento di induzione con mirikizumab rispetto al placebo: Settimana 16 - sPGA (0,1) PASI 90 Timepoint per la valutazione della non inferiorità del trattamento di induzione con mirikizumab rispetto a secukinumab: Settimana 16 - sPGA (0,1) PASI 90
|
|
E.5.2 | Secondary end point(s) |
PASI 75, PASI 100, = BSA with psoriasis involvement, PSS, DLQI, PASI 90, sPGA (0,1) |
PASI 75, PASI 100, = BSA con interessamento psoriasico, PSS, DLQI, PASI 90, sPGA (0,1)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Timepoints to assess whether mirikizumab induction dosing is superior to placebo: Week 4- PASI 75 Week 16- PASI 75, PASI 100, BSA =1% with psoriasis involvement, PSS symptoms, DLQI Timepoints to assess whether mirikizumab induction dosing is noninferior to secukinumab: Week 24- PASI 90 Week 52- sPGA (0,1), PASI 90, PASI 100 Timepoint to assess whether mirikizumab maintenance Q8W dosing is superior to secukinumab Week 52- sPGA (0,1) PASI 90 |
Timepoint per la valutazione della superiorità del trattamento di induzione con mirikizumab rispetto al placebo: Settimana 4 - PASI 75 Settimana 16 - PASI 75, PASI 100, BSA =1% con interessamento psoriasico, PSS per sintomatologia, DLQI Timepoint per la valutazione della non inferiorità del trattamento di induzione con mirikizumab rispetto a secukinumab: Settimana 24 - PASI 90 Settimana 52 - sPGA (0,1) PASI 90, PASI 100 Timepoint per la valutazione della superiorità del trattamento di mantenimento con mirikizumab Q8W rispetto a secukinumab Settimana 52 - sPGA (0,1) PASI 90
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 71 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Israel |
Japan |
Korea, Republic of |
United States |
France |
Germany |
Italy |
Poland |
Spain |
United Kingdom |
Argentina |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |